Last reviewed · How we verify

ESMOLOL HYDROCHLORIDE

FDA-approved withdrawn Small molecule Quality 35/100

Esmolol selectively blocks beta 1 adrenergic receptors in the heart, with rapid onset and short duration.

At a glance

Generic nameESMOLOL HYDROCHLORIDE
Targetbeta 1 receptors, beta 2 receptors
ModalitySmall molecule
PhaseFDA-approved
First approval1986

Mechanism of action

Esmolol is a cardioselective beta-blocker that primarily targets beta 1 receptors in the heart, reducing heart rate and contractility. At higher doses, it can also affect beta 2 receptors in the lungs and blood vessels.

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: